Physician profile
Mohammad Alsharabati
NPI 1174748180
$6,533.35
in general payments reported to CMS, 2019-2025
37 companies · $1,015 in 2025
The $1,015 reported for 2025 was more than what a typical Neuromuscular Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $530).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $556 · 2020: $2,523 · 2021: $1,146 · 2022: $434 · 2023: $173 · 2024: $686 · 2025: $1,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,757 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,756.96 |
| Education | $116.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $1,589.58 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $1,395.56 | 2019-2025 | Ultomiris |
| Abbvie INC. | $783.87 | 2021-2025 | Qulipta, Ubrelvy |
| Supernus Pharmaceuticals, INC. | $256.83 | 2019-2021 | |
| Lundbeck LLC | $248.06 | 2019-2024 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $214.34 | 2020-2025 | Austedo Xr |
| Lilly USA, LLC | $202.83 | 2019-2024 | Kisunla |
| Janssen Biotech, INC. | $198.70 | 2025 | |
| Allergan, INC. | $159.04 | 2020-2022 | |
| Genentech USA, INC. | $135.35 | 2021-2025 | Ocrevus Zunovo |
| Eisai INC. | $121.83 | 2024 | |
| Akcea Therapeutics, INC. | $107.73 | 2019 | |
| Novartis Pharmaceuticals Corporation | $107.34 | 2022-2025 | |
| Biogen, INC. | $102.57 | 2019-2025 | Vumerity, Tysabri |
| Tanabe Pharma America, INC. | $95.15 | 2019-2025 | Radicava |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $94.88 | 2025 | Nayzilam |
| Catalyst Pharmaceuticals, INC. | $74.75 | 2019-2025 | |
| Argenx US, INC. | $71.83 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Amgen INC. | $61.63 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $52.75 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $49.58 | 2021 | |
| Upsher-Smith Laboratories LLC | $48.58 | 2021 | |
| Genzyme Corporation | $45.50 | 2025 | |
| Emd Serono, INC. | $41.42 | 2025 | |
| Vanda Pharmaceuticals INC. | $35.92 | 2025 | Ponvory |
| Biohaven Pharmaceutical Holding Company LTD. | $31.80 | 2022 | |
| Pfizer INC. | $29.88 | 2021 | |
| Mallinckrodt Hospital Products INC. | $25.57 | 2025 | Acthar |
| Impel Pharmaceuticals LLC | $20.47 | 2025 | Trudhesa |
| Jazz Pharmaceuticals INC. | $20.23 | 2025 | |
| Acadia Pharmaceuticals INC | $19.04 | 2022 | |
| Kyowa Kirin, INC. | $18.83 | 2020 | |
| Janssen Pharmaceuticals, INC | $17.90 | 2025 | |
| Grt US Holding, INC. | $15.79 | 2021 | |
| Aucta Pharmaceuticals, INC. | $15.43 | 2025 | Motpoly Xr |
| Strongbridge US INC. | $11.71 | 2020 | |
| Amneal Pharmaceuticals LLC | $11.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Alsharabati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.